Mood disorders are glial disorders: evidence from in vivo studies.
It has recently been suggested that mood disorders can be characterized by glial pathology as indicated by histopathological postmortem findings. Here, we review studies investigating the glial marker S100B in serum of patients with mood disorders. This protein might act as a growth and differentiation factor. It is located in, and may actively be released by, astro- and oligodendrocytes. Studies consistently show that S100B is elevated in mood disorders; more strongly in major depressive than bipolar disorder. Successful antidepressive treatment reduces S100B in major depression whereas there is no evidence of treatment effects in mania. In contrast to the glial marker S100B, the neuronal marker protein neuron-specific enolase is unaltered. By indicating glial alterations without neuronal changes, serum S100B studies confirm specific glial pathology in mood disorders in vivo. S100B can be regarded as a potential diagnostic biomarker for mood disorders and as a biomarker for successful antidepressive treatment.
Schroeter
Matthias L
ML
Department of Psychiatry, Queen Elizabeth Hospital, 10362 Berlin, Germany.
Abdul-Khaliq
Hashim
H
Sacher
Julia
J
Steiner
Johann
J
Blasig
Ingolf E
IE
Mueller
Karsten
K